Skip to search formSkip to main contentSkip to account menu

JNJ 26481585

Known as: HDAC Inhibitor JNJ-26481585, JNJ-26481585, JNJ26481585 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Hydroxamic AcidsQuisinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes
To develop novel CNS penetrant HDAC inhibitors, a new series of HDAC inhibitors having benzoheterocycle were designed… 
2018
2018
Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Review
2017
Review
2017
Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets
Epigenetic modifications are heritable changes in gene expression that do not directly alter DNA sequence. These modifications… 
2014
2014
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program
Quisinostat (JNJ‐26481585) is a second‐generation pyrimidyl‐hydroxamic acid histone deacetylase (HDAC) inhibitor with high… 
2014
2014
Effect of Histone Deacetylase Inhibitor JNJ-26481585 in Pain
Recent studies have shown that histone deacetylase (HDAC) inhibitors can alleviate inflammatory and neuropathic pain. We… 
Highly Cited
2010
Highly Cited
2010
Preclinical anti‐myeloma activity of the novel HDAC‐inhibitor JNJ‐26481585
Pharmacological inhibitors of histone deacetylases (HDACs) are currently being developed and tested as anti‐cancer agents and may… 
Highly Cited
2009
Highly Cited
2009
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
The proteasome inhibitor bortezomib (Velcade) is currently approved as second-line treatment of multiple myeloma (MM). MM-related… 
Highly Cited
2009
Highly Cited
2009
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models
Multiple myeloma (MM) is a B-cell malignancy, which often remains incurable because of the development of drug resistance… 
2009
2009
Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT…
Histone deacetylase (HDAC) inhibitors such as vorinostat (suberoylanilide hydroxamic acid), valproic acid, romidepsin (FK-228… 
2004
2004
Purchase of Aton spotlights HDAC inhibitors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)